DYN vs NVST
Dyne Therapeutics, Inc. vs Envista Holdings — AI-powered side-by-side comparison
DYN
Dyne Therapeutics, Inc.
62
Buy
VS
NVST
Envista Holdings
76
Strong Buy
| Metric | DYN | NVST |
|---|
| AI Score |
62
|
76
|
| Price |
$26.70
|
$28.51
|
| P/E Ratio |
-8.02×
|
48.34×
|
| ROE |
-45.9%
|
1.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
55.5%
|
| Debt / Equity |
0.03×
|
0.52×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
71.9
|
59.3
|
| Beta |
1.084
|
0.861
|
| Expected Upside |
—
|
+1.4%
|
AI Committee View
Current Innellis committee reasoning for DYN versus NVST.
NVST leads by 14 points.
NVST scores 76/100 (Strong Buy) versus DYN at 62/100 (Buy).
DYN Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.15) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -64.3% -- cheap may mean cheap for a reason — Value
- RSI at 72 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
NVST Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Risk/reward is unfavorable: 14.2% downside vs 1.4% upside.